A recent scientific review published in the journal Pharmacology & Therapeutics suggests that cannabinoids found in medical cannabis could enhance the effectiveness of chemotherapy treatments while reducing their side effects. The 23-page review evaluates a range of both clinical and preclinical studies primarily focused on cancers such as glioblastoma, various hematological malignancies, and breast cancer.
The authors of the study, researchers from the Institute of Pharmacology and Toxicology at Rostock University Medical Center in Germany, summarize the findings by stating that existing data implies cannabinoids could improve the efficacy of chemotherapy agents and mitigate the adverse effects commonly associated with cancer treatments. The review emphasizes that while preclinical studies have primarily examined the toxicity of cannabinoids on cancer cells, further exploration is needed regarding their broader impacts on the immune system, angiogenesis (the formation of new blood vessels), and cancer metastasis.
Two main areas of interest stand out in the study: the potential for cannabinoids to enhance the effectiveness of chemotherapy and their ability to alleviate side effects. The review references a Phase 1b clinical study from 2021, which indicated that patients receiving a combination of THC-CBD oral spray and the chemotherapy drug temozolomide had improved survival rates compared to those who did not receive the cannabis treatment. The assessment also encompasses various cancers including leukemia, skin cancer, and colorectal cancer.
In terms of side effects, the report discusses cannabinoids’ well-documented antiemetic properties, which help alleviate nausea—a common side effect of chemotherapy. However, it also highlights emerging research suggesting that cannabinoids may positively influence other chemotherapy-related side effects such as peripheral neuropathy, nephrotoxicity, cardiotoxicity, cystitis, and mucositis. Additionally, cannabinoids are frequently used to manage chronic pain related to cancer.
Despite the promising findings, the authors caution that the interaction between cannabinoids and chemotherapy drugs is complex and not yet fully understood. They call for more rigorous clinical trials across various cancer types to validate cannabinoids as a supplementary treatment alongside existing chemotherapy regimens. The review urges further investigations into potential negative interactions that could arise from using cannabinoids with chemotherapy, emphasizing the need for comprehensive studies to explore the relationship between different routes of cannabinoid administration and their effectiveness.
The study’s conclusions echo a separate meta-analysis published last month, which analyzed data from 10,641 peer-reviewed studies on medical cannabis and its impact on cancer-related symptoms. This analysis found a strong scientific consensus regarding cannabis’s therapeutic benefits, particularly in managing symptoms associated with cancer treatments. Researchers noted that for every study indicating ineffectiveness, there were three demonstrating positive results.
The mounting evidence highlights a growing acceptance of cannabis in cancer care, although questions remain about accessibility and affordability. A report from the National Cancer Institute (NCI) noted that between 20% and 40% of cancer patients utilize cannabis products to alleviate treatment-related side effects, with the popularity of cannabis tracking alongside the legalization of medical cannabis in many states.
In summary, while cannabinoids present promising avenues for enhancing chemotherapy and managing its side effects, further research is essential to fully understand their potential roles in cancer treatment.
English 
Spanish 
German 
Czech